Incannex Healthcare Inc. (IXHL): EBITDA
-$22.79M
Year ended 2026-06-30
-$19.49M
Trailing 12 months to 2026-09-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$22.79M | n/m | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | -$23.54M | n/m | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | -$29.94M | n/m | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | -$49.58M | n/a | 2024-09-30, From 2022-07-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | -$22.79M | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.01M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $38.59M | +12.5% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.06M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $3.16B | +317.9% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $270.0K | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | -$21.57M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
Compare IXHL, TXMD, NATR, LSTA side by side · Screen every company in Pharmaceutical Preparations ↗